Application of enoxacin in prevention and/or treatment of flavivirus infection

A technology of enoxacin and flavivirus, which is applied in antiviral agents, medical preparations containing active ingredients, and resistance to vector-borne diseases, etc., to achieve the effect of inhibiting replication

Active Publication Date: 2020-06-02
ACADEMY OF MILITARY MEDICAL SCI +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are currently no reports that enoxacin has antiviral effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of enoxacin in prevention and/or treatment of flavivirus infection
  • Application of enoxacin in prevention and/or treatment of flavivirus infection
  • Application of enoxacin in prevention and/or treatment of flavivirus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] This example is used to illustrate that enoxacin used in the present invention has an inhibitory effect on the infection of Zika virus on neural precursor cells.

[0035] Treat human neural precursor cells (differentiated from human embryonic stem cells, purchased from Wicll, USA, No. H9, the same below), the concentration of enoxacin in the treatment system was 100 μM, and the concentration of cells was 2×10 5 Individuals / mL, infected with Zika virus (GZ01 strain, GenBank accession number KU820898) after 24 hours, the multiplicity of infection (MOI)=2. After the virus was incubated for 1 hour, replace with 1 mL of new culture solution containing 100 μM enoxacin (purchased from Stemcell, including NeuroCult-XF Proliferation MediuKit, product number 05761; 20 ng / mL EGF, product number 78006; 10 ng / mL bFGF, Product number 78003; 2 μg / mL Heparin, product number 07980, the same below). After 48 hours, the cells were fixed, and the primary antibody of Zika virus envelope p...

Embodiment 2

[0037] This example is used to illustrate that enoxacin has an inhibitory effect on the replication of different strains of flaviviruses on neural precursor cells.

[0038] Human neural precursor cells were treated with enoxacin (dissolved in DMSO), the concentration of enoxacin in the treatment system was 100 μM, and the concentration of cells was 10 5Individuals / mL, infected with Zika virus (SZ01, FSS13025, MR766 strain, GenBank accession numbers are KU866423, KU955593 and AY632535 ​​respectively) after 24 hours, MOI=2. After the virus was incubated for 1 hour, replace with 1 mL of new culture solution containing 100 μM enoxacin. After 48 hours, take the virus supernatant, extract RNA (the kit used was purchased from Thermo Fisher Scientific, USA, No. 12183018A, the same below), and detect viral RNA by real-time fluorescent quantitative PCR (see Table 1 for primers, the same below). Copy number, human neural progenitor cells treated with DMSO (without enoxacin) were used as...

Embodiment 3

[0044] This embodiment is used to illustrate the IC of enoxacin anti-Zika virus infection 50 Test Results.

[0045] Enoxacin was serially diluted 2 times to make the final use concentration from 200 μM to 3.125 μM. Treat human neural precursor cells, the cell concentration in the treatment system is 2×10 5 individual / mL, infected with Zika virus (GZ01 strain) after 24 hours, MOI=2. After the virus was incubated for 1 hour, 1 mL of culture medium containing gradient concentrations of enoxacin was replaced with new ones. After 48 hours, the virus supernatant was taken to extract RNA, real-time fluorescent quantitative PCR was used to detect the copy number of virus RNA, and the IC was obtained by using GraphPad 7.0 software to process statistics 50 =51.99, see the result image 3 .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of virus infection treatment and discloses application of enoxacin in prevention and / or treatment of flavivirus infection. By using enoxacin, infection of flavivirus(especially zika virus) can be effectively prevented and / or treated, and virus genome duplication can be inhibited. The application of enoxacin has an exact anti-virus effect.

Description

technical field [0001] The invention relates to the field of virus infection treatment, in particular to the application of enoxacin in preventing and / or treating flavivirus infection. Background technique [0002] Flaviviruses are a large group of enveloped single positive-sense RNA viruses. This type of virus is transmitted by blood-sucking arthropods (mosquitoes, ticks, sandflies, etc.) to cause infection. Previously classified as an arbovirus. The main flaviviruses prevalent in my country are Japanese encephalitis virus, forest encephalitis virus and dengue virus. [0003] Zika virus (ZIKV) belongs to the Flavivirus genus of the family Flaviviridae, mainly including African and Asian strains. The Asian strain of Zika virus has recently been confirmed to be associated with fetal microcephaly. The main reason is that the strain can infect the immature central nervous system, and mainly infect the neural precursor cells (neural precursor cells, NPCs), and eventually caus...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/496A61P31/14
CPCA61K31/496A61P31/14Y02A50/30
Inventor 秦成峰周溪胡宝洋徐炎鹏邱洋张博雅陈桂来
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap